{"id":"topical-tacrolimus-or-pimecrolimus","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Pruritus"},{"rate":"5-10%","effect":"Skin burning sensation"},{"rate":"5-10%","effect":"Skin irritation"},{"rate":"1-5%","effect":"Allergic contact dermatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"They work by inhibiting the calcineurin enzyme, which is necessary for the activation of T-lymphocytes. This leads to a decrease in the production of pro-inflammatory cytokines and a reduction in the immune response. As a result, they are effective in treating inflammatory skin conditions such as atopic dermatitis.","oneSentence":"Topical tacrolimus and pimecrolimus are calcineurin inhibitors that suppress the immune system by blocking the activation of T-lymphocytes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:30.937Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT06241118","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-02-29","conditions":"Dermatitis Atopic","enrollment":390}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3163,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Topical tacrolimus or pimecrolimus","genericName":"Topical tacrolimus or pimecrolimus","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Topical tacrolimus and pimecrolimus are calcineurin inhibitors that suppress the immune system by blocking the activation of T-lymphocytes. Used for Moderate to severe atopic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}